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1. Introduction
Evaluation of liver biopsy for tumour diagnostics is a highly practical task with major clini‐
cal influence. The liver is frequently affected by wide spectrum of neoplasms including be‐
nign tumours as well as primary malignancies [1-3]. In addition, due to the rich dual blood
flow to liver, secondary malignant tumours also often develop here. In order to ensure the
optimal management of the patient, a correct diagnosis is necessary. At present, biopsy is
the gold standard in oncology [4-5].
The scope of liver neoplasms can be following. The benign tumours include hepatic adeno‐
ma, bile duct adenoma, cavernous haemangioma and angiomyolipoma, among others. The
primary liver malignancies embrace hepatocellular carcinoma [6,7], cholangiocarcinoma [3]
and hepatoblastoma [8]. The diagnostics of hepatocellular carcinoma (HCC) is especially ur‐
gent topic due to high incidence in Asia and rising – in Europe and USA, possibly because
of high prevalence of chronic hepatitis C [4,9]. Also, prognostic data should be reported in‐
cluding the features of early vs. progressed HCC, presence of stem cell immunophenotype,
multicentric growth or metastatic spread [7]. Among mesenchymal malignant tumours, epi‐
thelioid haemangioendothelioma and angiosarcoma [10,11] are notable. Metastatic tumours
represent the bulk of malignancies in Western countries [2]. Cystic liver tumours include
biliary cystadenoma and biliary cystadenocarcinoma [12-14].
Most of the above mentioned neoplastic processes can be diagnosed in core biopsy. The key
aspects include the following. First, the biopsy must be representative regarding the biologi‐
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cal process and radiologically detected changes [15]. Further, the obtained tissue must be
subjected to adequate technological process. Innovations here allow shortening the turnover
time significantly. Next, the evaluation of morphology must be done searching for the char‐
acteristic traits of the above noticed tumours. However, due to the limited tissue amount in
the biopsy, the tumour architecture sometimes is difficult to identify embarrassing the dis‐
tinction between nodular hyperplastic process, benign tumour or low-grade malignancy. In
contrast, high-grade malignancies can show significant cytological atypia by few signs of
differentiation embarrassing the detection of histogenesis [6] and the distinction between
primary and metastatic tumour.
Immunohistochemical markers as glypican-3 [1], Hep Par 1 [3,6], CD10 [3], alpha-fetopro‐
tein [6] and TTF-1 [16] are useful in the HCC diagnostics. Alterations of CD31 and CD34-
positive endothelial cell network reflect vascular remodelling during hepatic carcinogenesis
[7]. Cytokeratin (CK) 19 and 7 are characteristic for cholangiocellular carcinoma [3]. In meta‐
stases, organospecific markers including CDX2, mammaglobin, nuclear expression of TTF-1
or presence of neuroendocrine markers can confirm extra-hepatic origin [17]. As colorectal,
breast, lung and neuroendocrine cancers are frequent cause of metastatic liver damage [2] high
diagnostic value of immunohistochemistry (IHC) can be expected. However, the exact detec‐
tion of histogenesis can be difficult with metastatic pancreatic or gastric tumours and high-
grade malignancies. IHC is mandatory for the diagnostics of haematological neoplasms and
epithelioid haemangioendothelioma. Assessment of tumour biological potential can be done
by IHC, evaluating Ki-67, Cyclin D1, FOXJ1, stem cell markers, matrix metalloproteinases and
other markers [7-8,18-22]. Novel markers appear continuously as heat-shock protein 70 [23].
Nowadays, pathology is not any more purely descriptive but it is becoming more functional
and clinically relevant. The classic morphologic characteristics must be combined with inte‐
grated evaluation of neoplastic process in the liver, including histogenesis, grading, clonal
changes, type and extent of vascularisation, immunophenotype, heterogeneity, prediction of
treatment sensitivity and the clinical behaviour [7]. New technologies as proteomic profiling
and genomic marker analysis should be applied in the evaluation of liver tumours [4]. Mi‐
croRNA studies can lead to new findings in cancer pathogenesis and prediction of treatment
efficacy [24,25].
The aim of the following chapter is to describe morphological and immunohistochemical
characteristics of primary and secondary liver tumours in order to develop logistic basis for
differential diagnosis of these processes in biopsy materials. Short discussion about the gen‐
esis and clinical course of each tumour will be included as well.
2. Benign epithelial liver tumours
Liver cell adenoma and bile duct adenoma will be discussed here. The regenerative process‐
es with the emphasis on focal nodular hyperplasia are described considering the differential
diagnosis.
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2.1. Liver cell adenoma and its differential diagnosis with focal nodular hyperplasia
Liver cell adenoma or hepatic adenoma is defined as benign tumour arising from hepato‐
cytes. The epidemiology is characterised by female predominance (90%) and strong associa‐
tion with oral contraceptive use [26-27] as 85% of affected persons have such history. Liver
cell adenoma was rare before the era of oral contraceptives [27]. At present, the incidence
has increased but is still low: 3-4 /100 000 per year in long-term users of oral contraception
[27-29]. The patients mostly are 20-39 years old. The other risk factors of hepatic adenoma
include androgen burden. The tumours can also arise spontaneously or occasionally can be
related to glycogen storage diseases or diabetes mellitus. Clinically, the patients mostly are
symptomatic. Abdominal fullness can be attributed to the presence of mass lesion; pain can
be caused by necrosis [27]. Rupture and bleeding (40%) represent dangerous complications
[27,29-31]; the risk of these events is increased in pregnant ladies affected by liver cell adeno‐
ma due to prior use of hormonal contraceptives. Risk of malignant transformation also is
recognised [29,32]. By literature analysis, Farges and Dokmak concluded that 5% of resected
hepatic adenomas bear HCC foci [32]. The risk of malignant transformation is higher in ade‐
nomas exceeding the size of 5 cm irrespectively of the number of adenomas as well as in
males. Grossly, liver cell adenomas are mostly unifocal (80%) and subcapsular. The tumours
can be quite large (5-20 cm). In most cases (75%) adenomas are encapsulated [27]. However,
the capsule can be thin or absent [10]. In contrast to HCC, adenomas usually are not associ‐
ated with cirrhosis [31]. Otherwise, radiological similarities exist between adenoma and
HCC as both can be large, have rich vascularity and can undergo necrosis [31]. Microscopi‐
cally, the tumour is composed by hepatocytes lacking anaplasia and arranged in thin (1-2
cells) trabeculae [27,29]. Cellular atypia and macrotrabeculae must be absent. Single arterio‐
les, a pair of arteriole and venule or isolated biliary ducts are scattered throughout the le‐
sion. However, well-formed triads enveloped in connective tissue are absent within the
lesion. The tumour can be distinguished from normal liver by larger size of neoplastic cells,
presence of capsule and lack of triad-containing portal tracts. Steatosis, hydropic degenera‐
tion or Mallory hyaline can be observed. Fibrous tissue, haemosiderin and calcifications can
develop in the consequence of haemorrhage. The immunophenotype is characterised by ex‐
pression of Hep Par 1 and other antigens that confirms the hepatic origin and by lower pro‐
liferation than in HCC. Molecular typing is emerging for liver cell adenoma as well. At
present, up to 4 molecular types are identified:
1. hepatic adenoma with TCF1 gene inactivation;
2. inflammatory hepatic adenoma;
3. beta-catenin-mutated non-inflammatory hepatic adenoma;
4. hepatic adenoma not displaying any before described feature or unsuitable for analysis [29].
The hepatic adenomas with TCF1 gene mutation comprise 35-40% of liver cell adenomas.
The patients are female. The tumour loses the expression and functions of hepatocyte nu‐
clear factor 1 (HNF1) encoded by TCF1  gene. Inactivation of the gene can be caused by
mutation in both alleles or by combination of a mutation and 12q deletion leading to loss
of heterozygosity in the corresponding region [33]. Germ-line mutation of HNF1 gene man‐
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ifests  as maturity-onset  diabetes of  the young (MODY),  type 3,  in association with liver
adenomatosis [34]. However, the spectrum of HNF1A somatic mutations in liver cell adeno‐
ma differs from that in patients with MODY3 and suggests genotoxic damage [35]. By IHC,
loss of liver fatty acid binding protein can be observed. Not surprisingly,  the adenomas
show steatosis [29].
Inflammatory hepatic adenomas constitute 50% of liver cell adenomas and can be associated
with obesity, smoking and alcohol use. Pathogenetically, inflammatory hepatic adenoma is
characterised by IL-6 pathway activation centred on gp130 protein in IL-6 receptor. The recep‐
tor can be subjected to ligand-independent activation due to mutation in IL6ST gene, or the
levels of gp130 can be elevated. The IL-6 receptor activation leads to recruitment of inflamma‐
tory cells through gp130-mediated production of chemokine CCL20. The mutation was found
in 60% of inflammatory adenomas [36]. However, the IL-6 pathway activation is universal in
the inflammatory hepatic adenoma. Microscopically, inflammatory infiltrates are observed in
addition to the architecture and cytologic details of adenoma. Occasional bile ductules, dilat‐
ed sinusoids and arterioles can be present. Haemorrhage is frequent. By IHC, expression of
acute phase reactants serum amyloid A and C-reactive protein is marked [29].
A group of hepatic adenomas is associated with beta-catenin mutation [37-38].The beta-cate‐
nin pathway is not affected in TCF1 inactivated group [29,38]. Beta-catenin activation can be
assayed by immunohistochemical over-expression of glutamine synthetase or by aberrant
nuclear localisation of beta-catenin. However, the tumours can show dysplastic changes
more characteristic for HCC thus possibly this group will be reclassified into well-differenti‐
ated HCC [29,36].
The last group of hepatic adenomas (5%) lacking TCF1 inactivation, inflammatory signature
and beta-catenin mutation [29] could represent distinct group with peculiar pathway of mo‐
lecular pathogenesis or result of technological shortcomings.
The differential diagnosis of hepatic adenoma in biopsy includes low-grade HCC and hy‐
perplastic lesions like focal nodular hyperplasia, nodular regenerative hyperplasia and par‐
tial nodular transformation [27].
Focal nodular hyperplasia (FNH) is a comparatively frequent differential diagnosis of hepat‐
ic adenoma. The FNH incidence is estimated as 3% [29-30,39]. FNH is characterised by pres‐
ence of hypervascular stellate scar in liver parenchymal nodule. The blood vessels are
located in the middle of star-like fibrous tissue while the periphery is occupied by proliferat‐
ing bile ductules. The morphologically remarkable abundant vascularity is in accordance
with the hypothesis of the FNH origin due to microscopic arterial malformation [40-42]. The
crucial difference between FNH and adenoma is pathogenetic as the former is thought to be
hyperplastic lesion, while adenoma is a neoplasm. The presence of stellate scar and lack of
peripheral capsule in FNH contrasts with presence of peripheral capsule and almost com‐
plete lack of connective tissue or portal triads within adenoma. If the architecture is incom‐
pletely represented in the biopsy, molecular characteristics should be able to discriminate
between the two inherently different processes, the hyperplasia and tumour. The immuno‐
histochemical markers of biliary differentiation have been employed in the differential diag‐
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nostics between FNH and hepatic adenoma. As described by Walther and Jain, CK19 and
CD56 detect rich network of proliferating biliary ducts in the fibrous septa of FNH but re‐
veal only few isolated ducts within the parenchyma of hepatic adenoma. Expression of CK7
is remarkable for the focal presence in parenchyma of liver cell adenoma in contrast to FNH
while both lesions show expression of CK7 in biliary ducts. Thus, panel of CK19, CD56 and
CK7 can be advised to solve the differential diagnosis in core biopsy [29]. Immunohisto‐
chemical expression pattern of glutamine synthetase differs between normal liver tissue,
FNH and liver cell tumours as well. In healthy tissue, glutamine synthetase is present in per‐
ivenular hepatocytes. These positive areas are expanded in FNH [39]. In hepatic adenomas,
glutamine synthetase expression is either diffuse of negative. In the last situation, the nega‐
tivity in the tumour can be incomplete, with focally preserved expression in the tumour pe‐
riphery [29] and thus difficult to interpret, especially in small biopsies where the preserved
positive focus seems to be dominant.
In nodular regenerative hyperplasia, the liver contains many small regenerative nodules.
Partial nodular transformation affects hilar area and is characterised by group of regenera‐
tive nodules surrounded by fibrous tissue [27].
Considering the differential diagnosis with HCC, thick trabecular cords, cytologic anaplasia
and invasive growth reveal the malignant biological potential. The thickening of trabeculae
is defined as presence of more than 2 cell layers in the trabeculae. The anaplasia is recog‐
nised by nuclear hyperchromasia, prominent nucleoli and increase in the nucleo: cytoplas‐
mic ratio. Presence of mitoses practically excludes the diagnosis of hepatic adenoma.
Atypical mitoses are absolute evidence of malignancy. The invasive growth can manifest as
invasion through the capsule, infiltration into liver parenchyma and true invasion into
blood vessels [27].
2.2. Bile duct adenoma
Bile duct adenoma is defined as a benign neoplasm of portal bile ducts. The epidemiologic
data suggest rare occurrence. However, as the tumours mostly are small and asymptomatic
[27], the true incidence and prevalence is unknown. Grossly, bile duct adenomas are mostly
solitary (83%), subcapsular (95%) and small (below 1 cm). By light microscopy, the lesion is
characterised by demarcated proliferation of bile ducts lacking atypia. The immunopheno‐
type repeats the staining characteristics of biliary ducts exhibiting expression of cytokeratins
7 and 19 [27]. The differential diagnosis can include small foci of low-grade cholangiocarci‐
noma or metastatic low-grade adenocarcinoma, but the benign cytological appearance is
helpful. Von Meyenburg hamartoma differs from bile duct adenoma, as the hamartomas
would be multiple and show traits of cholestasis. However, the exact separation might not
be of crucial importance due to benign course of biliary adenoma and pathogenetic sugges‐
tion that biliary adenoma represent a reactive process rather than true neoplasm.
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3. Malignant epithelial primary liver tumours
Three primary liver tumours are of utmost importance. Hepatocellular carcinoma is the
most frequent primary epithelial liver tumour with grave prognosis. Cholangiocarcinoma
ranks second by the incidence except for endemic regions. Hepatoblastoma is notable for the
occurrence in the infancy.
3.1. Hepatocellular carcinoma
Hepatocellular carcinoma is defined as malignant tumour developing from hepatocytes
and/or showing hepatocellular differentiation. It is the most common primary malignant tu‐
mour of the liver constituting 80-85% of primary epithelial liver malignancies [29,43]. Con‐
sidering the epidemiology, the worldwide burden of hepatocellular carcinoma can reach 1
million of new cases per year. The incidence shows major geographic differences. HCC is
the 2nd most common cancer in Asia, and the 4th – in Africa [10]. The annual age-standar‐
dised incidence is the highest in East Asia, including China and Japan. Low-risk areas com‐
prise Europe, esp. northern and western parts; North and South America, Australia and
New Zealand [10].The age-adjusted incidence rates in Mozambique are as high as 112.9 and
30.8/100 000 in males and females, respectively. In China these values reach 34.4 and 11.6. In
contrast, the age-adjusted incidence rates in British males and females are 1.6 and 0.8, re‐
spectively [31]. The HCC risk factors include liver cirrhosis independently of cause, chronic
hepatitis B or C, ethanol consumption and non-alcoholic liver steatosis as well as mycotox‐
ins. The aflatoxin B1 or other mycotoxins produced by Aspergillus fungi could be responsible
for part of HCC in areas where grains, rice and peanuts are stored in hot and humid condi‐
tions [31]. Most of HCC cases develop from dysplastic cirrhotic nodule [29], thus the differ‐
ential diagnostics between dysplastic nodule and cancer represent evaluation of one point in
a complex road of pathogenesis. Clinically, most of the patients approach doctor due to
symptoms attributable to mass lesion in the liver (abdominal pain, sensation of fullness), tu‐
mour-related intoxication (weight loss, weakness, lack of appetite) and loss of liver func‐
tions (jaundice). Alternatively, the symptoms can be related to pre-existing cirrhosis and the
tumour could be identified during routine control of cirrhotic patient or during workup for
unspecific or unrelated symptoms [31]. Radiologically, the number and size of tumour
masses can be evaluated. Ultrasonography can be used for screening. Typical findings re‐
garding vascularity include hypervascularity and thrombosis of portal vein, frequently due
to invasion. If it is necessary to confirm invasion into portal vein, biopsy can be obtained
from it [31].
By microscopy, the typical patterns include trabecular, acinar and ductular structure. The
neoplastic cells in low-grade cases resemble liver cells by possessing wide eosinophilic cyto‐
plasm and distinct cell borders. Nuclear atypia is present and nucleo: cytoplasmic ratio is
increased, although to different degree. Mitoses can be present; atypical mitoses can be ob‐
served (Figure 1). The architecture shows unequivocal deviations from normal structure
such as thick trabeculae with more than 2 cell layers (in contrast to adenoma), solid areas,
duct-like or gland-like structures. However, careful evaluation of the architecture under
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high power magnification must be carried out. There are many secondary phenomena rais‐
ing the similarity between HCC and liver tissue: presence of macrovesicular or microvesicu‐
lar fat, Mallory hyaline and bile. The capillaries can be dilated [27]. Among the
histochemical staining methods, absent reticulin staining [44] is characteristic. PAS stain can
reveal glycogen and intracytoplasmic globules; the latter structure remains positive after di‐
astase digestion [27,44]. With some experience, morphology is helpful to distinguish finely
granular glycogen or rounded globules in HCC from mucus droplets in metastatic adeno‐
carcinoma or cholangiocarcinoma.
Figure 1. Hepatocellular carcinoma displaying marked cytologic atypia. Note the presence of atypical mitosis. Haematox‐
ylin-eosin (HE), original magnification (OM) 100x.
Fibrolamellar hepatocellular carcinoma (FLHC) has distinctive aetiology, epidemiology and
course. The general HCC risk factors are not associated with this subtype [31]. FLHC is rare,
constituting only 1-4% of HCC [27]. It is less common in high-risk areas than in North
America and Europe. The patients are young adults or even children [10]. FLHC is diag‐
nosed at the mean age of 25 years in contrast to mean age of 52 years in typical HCC patient
group [27]. Controversial data are reported about the sex predilection: some but not all au‐
thors have noted that females are mostly affected [10,31]. Clinically, symptoms attributable
to liver enlargement, parenchymal damage (elevated liver enzyme level) or tumour-related
intoxication (weight loss or fever) can be present. Cirrhosis is absent. The tumour can be
multifocal, and metastases can affect lungs and regional lymph nodes [31]. The histological
structure is remarkable for the lamellar fibrosis. The stroma is composed of thick, parallel
strands of hyalinised collagen [27]. The cells are large, polygonal, with wide eosinophilic cy‐
toplasm. The vesicular nuclei possess large nucleoli. Cytoplasmic pale bodies are more fre‐
quent (up to 50% of cases) and more abundant than in other types [10,27]. The pale bodies
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are rounded and very lightly eosinophilic thus staining paler than the surrounding cyto‐
plasm. These structures represent cystically dilated endoplasmic reticulum. Pale bodies can
be positive for fibrinogen by IHC. The immunophenotype is remarkable for diffuse expres‐
sion of CK7. The hepatocellular differentiation can be confirmed by Hep Par 1; alpha-feto‐
protein is present in approximately 20% of cases. The FLHC prognosis is better than in the
general group. The mean survival is 32 months in contrast to 5.9 months in trabecular HCC
[27]. However, it is found that the beneficial prognosis of FLHC is different from cancer in
cirrhotic liver but not from HCC in the absence of liver cirrhosis [10].
IHC has an important role in the diagnostics of HCC. Frequently tested antigens include
glypican-3, Hep Par 1, alpha-fetoprotein, CD10, carcinoembryonic antigen CEA, TTF-1, argi‐
nase-1, evaluation of cytokeratins and endothelial network as well as MOC-31 and markers
of extra-hepatic tumours.
Glypican-3 is a cell surface protein [1] that is involved in the control of cell proliferation and
survival. Glypican-3-knockout mice exhibit alterations in Wnt signalling [45]. Glypican-3 al‐
so interacts with Hedgehog signalling pathway [46]. In the practical surgical pathology, the
value of glypican-3 is associated with the cancer diagnostics as it is expressed in 70-75% of
HCC but not in benign liver tissue [48-49] or cholangiocellular carcinoma [1]. Hepatoblasto‐
ma can be positive as well. However, glypican-3 can be expressed in metastatic melanoma
[50], ovarian clear-cell carcinoma [51], choriocarcinoma, yolk sac tumour [52-53] as well as in
blastomas including neuroblastoma and Wilms’ tumour [54]. In addition, 10% of gastric can‐
cer cases are positive for glypican-3 [55]. In melanoma, 80% of tumours contain detectable
level of glypican-3 protein and mRNA [1]. Regarding ovarian cancer, the rate of glypican ex‐
pression could be as high as 18% of all ovarian cancer cases and 60% of clear cell carcinoma
cases [51]. However, negative reports regarding clear cell carcinoma of ovary are published
as well [53]. Glypican-3 is silenced in breast cancer, lung adenocarcinoma and mesothelioma
[56-58]. Another problem has been highlighted by Abdul-Al et al., who have described fre‐
quent granular cytoplasmic expression of glypican-3 in chronic active hepatitis C [59]. Re‐
generative changes were suggested as the explanation. Authors emphasized that
membranous staining was not observed in hepatitis [59]. Glypican-3 has prognostic signifi‐
cance in HCC as it is associated with poor prognosis [60] and shorter recurrence-free period
after liver transplantation [49]. The applications of glypican-3 could extend beyond liver bi‐
opsy – and return to it. It could possible to use glypican-3 plasma levels for diagnostics and
monitoring of HCC [61-63]. Immunotherapy could be guided towards glypican-3; the
present research is exploring both antibody and cell-based immunological mechanisms
[64-65]. Cancer vaccine could be generated against this molecule [1]. Glypican-3 is among
genes that are distinctly expressed in liver cancer stem cells; it is suggested that glypican
could be promising candidate for gene therapy without inducing damage to normal liver
stem cells [66].
Hep Par 1 is positive in normal liver, liver adenomas and HCC. The antibody was devel‐
oped in 1993 using an immunogen from failed liver allograft. The target antigen has been
identified as carbamoyl phosphate synthetase. This enzyme catalyses the rate-limiting step
in the urea cycle and is located in the mitochondria [67]. The specifity and sensitivity of this
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marker in HCC diagnostics exceeds 80% and has reached 90% in several studies [6,67]. Un‐
fortunately, sensitivity is lower in high-grade HCC. The expression in non-hepatocellular tu‐
mours including colorectal, pancreatic, breast, urothelial, prostate cancer, neuroendocrine
tumours, renal cell carcinoma, melanoma and angiomyolipoma is either negative or focal.
However, few gastric, colorectal and lung adenocarcinomas can be positive [6,67]. In the bi‐
opsy material, heterogeneity in the HCC can cause diagnostic problems [6].
Arginase-1 is an enzyme involved in the urea cycle as well. It is found in benign hepatocytes
and hepatocellular neoplasms. The antibody has received high sensitivity estimates of 96%
and favourable performance characteristics [68,69].
Alpha-fetoprotein is an oncofetal protein produced by the liver and yolk sac endoderm. The
antigen is remarkable for expression in malignant hepatocellular tumours (Figure 2) in con‐
trast to benign liver tissue, and for the high specifity. However, sensitivity is low (30-50%)
and heterogeneity adds further problems in biopsy evaluation [6]. Nevertheless, positive ex‐
pression is valuable.
Figure 2. Heterogeneous intense cytoplasmic expression of alpha-fetoprotein in hepatocellular carcinoma. Immuno‐
peroxidase (IP), anti-alpha-fetoprotein, OM 100x.
Polyclonal antibodies against carcinoembryonic antigen (CEA) yield positive reaction more
than in 70% of HCC cases, while monoclonal anti-CEA only rarely stains HCC. Reactivi‐
ty  with  polyclonal  CEA antibodies  mostly  is  observed in  canaliculi;  this  pattern can be
observed  in  benign  or  malignant  liver  tissues  and  is  attributable  to  cross-reaction  with
biliary glycoprotein on the canalicular surface [67]. The canalicular pattern is specific for
HCC and can be used to exclude cholangiocarcinoma and metastatic adenocarcinoma. It
is  not useful  in the differential  diagnosis between HCC and benign hepatocellular mass
Primary and Metastatic Tumours of the Liver: Expanding Scope of Morphological and Immunohistochemical Details...
http://dx.doi.org/10.5772/52838
123
lesions. Although good general sensitivity has been reported, it is higher in well or mod‐
erately  differentiated HCC that  present  less  problems regarding the  differential  diagno‐
sis with cholangiocellular carcinoma or metastasis [67]. Cytoplasmic stain is not observed
in healthy liver or benign neoplasms; it is characteristic of malignancy but seen mostly in
cholangiocellular  carcinoma  and  metastatic  neoplasms.  The  rate  of  cytokeratin  fraction
expression is  15% for CK7,  20% for CK20 and 10% for CK19.  Diffuse strong expression
of  endothelial  markers  CD31  and  CD34  is  not  characteristic  for  normal  liver  tissue  in
contrast  to  HCC [27].  The  visualisation  of  endothelial  layer  is  valuable  also  in  estimat‐
ing  the  thickness  of  trabeculae.  However,  pattern  of  diffuse,  strong  endothelial  marker
expression has low sensitivity of 20-40%. The patchy expression is also difficult to evalu‐
ate in liver biopsies.  The visualisation of  endothelium thus is  not  recommended for the
distinction between adenoma and carcinoma [6].
The transcription factor TTF-1 is expressed as intense granular cytoplasmic staining in nor‐
mal liver parenchyma [16] and hepatocellular tumours (Figure 3). The reaction is ensured by
cross-reactivity with hepatocyte mitochondrial antigen and is seen with the clone 8G7G3/1
[69]. The reported sensitivity is 60-70%. However, it parallels the expression of Hep Par 1
decreasing the practical value [6]. Its expression can be retained even in metastatic HCC [16].
Figure 3. Granular cytoplasmic expression of TTF-1 in hepatocellular carcinoma. IP, Anti-TTF-1, OM 400x.
MOC-31 is an epithelial cell surface glycoprotein of unknown function. Evaluating liver bi‐
opsies, it is valuable as non-hepatocellular marker. MOC-31 is negative in HCC but positive
in most metastatic adenocarcinomas and cholangiocellular cancer [67]. However, mesothe‐
lioma is MOC-31 negative as well; calretinin should be used in the panel to exclude this pos‐
sibility [17].
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Molecular subtyping is emerging for HCC. The subtypes are distinguished by high prolifer‐
ation and chromosomal instability; by activation of Wnt signalling pathway and by interfer‐
on signalling due to tumour-infiltrating cells [70-77].
The requests for clinically relevant classification have resulted in the separation of HCC into
early and progressed entities. The early HCC is recognized as small (not exceeding the diam‐
eter of 2 cm), well differentiated and lacking vascular invasion. The invasion into portal tracts
can be present and is highlighted by lack of proliferating ductules. Macrovesicular steatosis
is present in 40% of early HCC but appears mostly in Eastern cohorts. It can be attributable to
incomplete neoarterialisation – the process of portal tract replacement by unpaired arteries
outside the portal tracts. In early HCC, there is still comparatively large venous flow. The
tumours in general may be radiologically hypovascular. The early HCC is more likely to
become the biopsy target due to equivocal findings at imaging. Progressed HCC includes HCC
of higher grade (moderate or poor differentiation degree, G2 or G3), possessing vascular
invasion,  larger size or  stem/progenitor  cell  immunophenotype and mixed hepatobiliary
differentiation. The stem cell immunophenotype can be detected by IHC for CK19, EpCAM,
CD133, and mixed hepatobiliary immunophenotype – by expression of CK7 and CK19 [7]. The
5-year survival is 89% in the early HCC group in contrast to 48% in the progressed group. The
intrahepatic metastatic spread must be distinguished from multifocal carcinoma that is prog‐
nostically better disease. The multifocal disease is characterised by “nodule in nodule” struc‐
ture or by presence of at least one G1 nodule [7].
The differential diagnosis includes benign hepatic lesions, metastatic malignancies and chol‐
angiocarcinoma. IHC is of major importance. Markers, that are expressed both in benign
and malignant liver cells (CEA by polyclonal antibody, CD10, Hep Par 1, TTF-1 and (occa‐
sionally) cytokeratins [27]) identify the hepatocellular origin of tumour but cannot be used
to prove the malignant biological potential of suspicious biopsied tissue. If these are found
in high-grade tumour, diagnosis of HCC is preferable in contrast to metastasis. The expres‐
sion of alpha-fetoprotein and glypican-3 is typical for malignant tumour of hepatocellular
origin [27]. These findings are important in differential diagnosis with non-hepatocellular
and/or metastatic tumour in line with other markers specific for particular histogenesis. Re‐
garding the differential diagnosis of HCC and dysplastic cirrhotic nodule, a panel of immu‐
nohistochemical stains is recommended employing glypican-3, glutamine synthetase and
heat-shock protein 70 [48,78-80]. In biopsy, the panel has lower sensitivity although good
specifity: accuracy 60.8% for 3 markers and 78.4% for 2 markers with 100% specifity. The
findings were acceptable even in the group of low-grade HCC: the accuracy still was 57%
for 3 markers and 72.9% for 2 markers with 100% specifity [23].
HCC (except fibrolamellar type) mostly is associated either with cirrhosis or chronic active
hepatitis with fibrosis that has not reached the degree of cirrhosis. To facilitate the differen‐
tial diagnosis between HCC and liver adenoma or FNH it is wise to take separate biopsies‐
from the lesion and from distant liver tissues if possible.
The future pathways for molecular diagnostics of HCC include mRNA analysis of GPC3,
survivin and LYVE1 genes [78]. Glypican-3, encoded by GPC3, and survivin is up-regulated
Primary and Metastatic Tumours of the Liver: Expanding Scope of Morphological and Immunohistochemical Details...
http://dx.doi.org/10.5772/52838
125
in parenchymal HCC cells while LYVE1 protein is down regulated in endothelial cells in
case of malignancy. MYC pathway studies could also bring new information [29].
In  addition,  molecular  studies  can  predict  the  HCC prognosis.  Down-regulation  of  p57
accelerates the growth and invasion of HCC cells [18]. The reduced p57 expression corre‐
lates with larger tumour size, higher TNM stage, presence of extrahepatic metastases and
decreased survival. In cell lines, the down-regulation of p57 increases the expression of cyclin
D1 and CDK2, enhancing the cellular proliferation. The matrix metalloproteinase-1 (MMP-1)
and protease activated receptor-1 (PAR-1) are expressed in HCC but not in normal liver.
The up-regulation of MMP-1/PAR-1 axis has prognostic value [20] and potentially could be
used in the identification of malignancy.  Co-expression of stem cell  transcription factors
Oct4 and Nanog indicates aggressive tumour behaviour and predicts recurrence after HCC
resection [22]. FOXJ1 is over-expressed in HCC. It is associated with histological grade, poor
prognosis and with tumour cell proliferation [19]. Hedgehog signalling pathway mediates
invasion and metastasis of  HCC via ERK pathway. Up-regulation of cell  proliferation is
associated with down-regulation of p27 and p21 and up-regulation of cyclin D1 [81]. Osteo‐
pontin plays role in the proliferation of HCC through interaction with the cell surface recep‐
tor  CD44  [82]  and  is  considered  the  key  mediator  for  vasculogenic  mimicry  [83].  Bax-
interacting factor is over-expressed in HCC and correlates with shortened survival [84]. NY-
ESO-1  protein  is  a  potential  marker  for  early  recurrence  after  surgical  treatment  [85].
Hepatocyte nuclear factor 4 suppresses the HCC development [86]. Sulfatase 2 protects HCC
cells against apoptosis [87]. Interleukins as IL-17 and IL-6 have tumour-promoting role [88].
Interaction with matrix metalloproteinases 2 and 9 is likely [89]. Up-regulation of sirtuins
has  been identified [90].  Typing of  immune cells  in  biopsy is  mostly  done for  research
purposes [91]. If any of those parameters will show prognostic and predictive value, the
relevant IHC analysis should be included in the protocol of liver biopsy evaluation. The
technological  future  developments  include  virtual  microscopy.  Fractal  analysis  [92]  and
quantitative IHC can be applied [93].
Methylation studies have been carried out in HCC [94]. The expression of microRNAs is un‐
dergoing active analysis in HCC [95-96]. MicroRNAs are non-coding, short RNA molecules
that can bind to messenger RNA and to prevent their translation into protein, providing ad‐
ditional regulation of gene expression. MicroRNAs act as large-scale molecular switch due
to ability simultaneously down-regulate many genes. MicroRNA-181 down-regulates the
differentiation and maturation of hepatocytes [96]. Suppression of microRNA-181 expres‐
sion leads to reduced motility and invasion of HCC stem cells [25]. MicroRNA-182 could
promote metastasis [97]. MicroRNA-183 inhibits apoptosis [98]. MicroRNA expression can
be subjected to regulation with IL-6 [25]. Reduced expression of microRNA-26 in HCC is as‐
sociated with poor prognosis. However, better response of interferon alpha postoperative
adjuvant therapy can be expected [95]. MicroRNA-21 induces resistance to the anti-tumour
effect of interferon and fluorouracil combination therapy [99]. Circulating microRNAs are
valuable in tumour diagnosis and monitoring the treatment [24].
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3.2. Hepatoblastoma
Hepatoblastoma is defined as a primary malignant blastomatous liver tumour showing
complex differentiation towards fetal and embryonal hepatocytes as well as mature tissues
including osteoid, connective tissue and striated muscle. Epidemiologically, hepatoblastoma
is a rare malignant liver tumour of childhood with the incidence of 1 case / 1 million [8,10].
In children, hepatoblastoma is the most common primary liver tumour. Characteristically,
the tumour develops within first five years of life: 4% of hepatoblastomas are present at
birth, 69% have developed by 2 years of age and 90% - by 5 years of age. Only 3% of patients
are older than 15 years [100]. The risk of hepatoblastoma is increased in APC-mutation-car‐
rying children from familial adenomatous polyposis (FAP) kindreds. Clinically, enlarging
abdomen can be the first sign. The other possible manifestations include weight loss, ano‐
rexia, nausea, vomiting and abdominal pain. Jaundice is rarely observed [100]. Paraneoplas‐
tic syndromes can occur. Among those, anaemia and thrombocytosis are frequent.
Precocious puberty due to production of chorionic gonadotropin is rare. Grossly, the tu‐
mours mostly occur as single lesions [10] measuring 5-22 cm [100]. Pseudocapsule can de‐
velop due to compression of surrounding liver tissue. Microscopically, hepatoblastoma can
display any of different histological patterns, or combination of these patterns. The fetal epi‐
thelial differentiation is characterised by thin trabeculae of small cuboidal cells. The nuclei
are small and round with fine chromatin and small nucleolus. The cytoplasm can be either
clear or finely granular resulting in “light and dark” pattern under low magnification. Foci
of extramedullary haemopoesis can be present. The combined fetal and embryonal pattern
is characterised by presence of small tumour cells in solid or acinar groups. The small cells
have scant cytoplasm, higher nucleo: cytoplasmic ratio and coarse chromatin. Hepatoblasto‐
ma is called macrotrabecular if the cells compose 6-12 cell layers in the trabeculae in most of
the tumour. Larger cells are present in the macrotrabeculae in addition to fetal and embry‐
onal type. In teenagers, macrotrabecular hepatoblastoma must be differentiated from hepa‐
tocellular carcinoma. Small cell undifferentiated hepatoblastoma morphologically resembles
small cell cancer displaying solid small blue cell pattern with focal necrosis. Mixed epithelial
and mesenchymal hepatoblastomas contain mesenchymal components including fibrous tis‐
sue, osteoid, cartilage, striated muscle, bone or melanin [100]. Mixed epithelial and mesen‐
chymal hepatoblastoma with teratoid features is recognised by the presence of endodermal,
neuroectodermal and complex mesenchymal tissues. The neuroectodermal component can
comprise melanin, glial and neuronal cells [10].After treatment, connective tissue, necrosis
and signs of haemorrhage develop in association with residual neoplastic tissue, and squa‐
mous islands become more common. Immunohistochemically, expression of alpha-fetopro‐
tein, beta-catenin and cell cycle markers is associated with the histological pattern. The fetal
subtype is characterised by low proliferation that parallels the scant mitotic activity; alpha-
fetoprotein can be present and the expression of beta-catenin is retained in the membranous
localisation. The combined fetal and embryonal subtype is characterised by shift of beta-cat‐
enin expression towards the nuclei in higher grade embryonal component. An interesting
circular pattern can be observed. In the rounded cell groups, the middle is occupied by pro‐
genitor-type pale, small cells displaying low proliferative activity and nuclear expression of
beta-catenin. The progenitor-type cells are surrounded by intensively proliferating embry‐
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onal type cells characterised by mixed nuclear and cytoplasmic expression of beta-catenin.
The outermost layer of these concentric structures is composed by fetal type cells with low
proliferative activity and retained membranous expression of beta-catenin. The small cell
subtype lacks alpha-fetoprotein but has high proliferative activity, usually reaching 80%; cy‐
tokeratins are expressed as well. Even in the mixed epithelial and mesenchymal hepatoblas‐
toma, cytokeratins and alpha-fetoprotein can be expressed even in the ostecyte-like and
osteoblast-like cells embedded in or associated with the osteoid, correspondingly [10]. In the
study of Purcell et al., cyclin D1 and Ki-67 were two markers (out of 5, including also beta-
catenin, E-cadherin and alpha-fetoprotein) that were shown to have prognostic value re‐
garding survival [8].
3.3. Cholangiocarcinoma
Cholangiocarcinoma (CC) is defined as malignant epithelial liver tumour with biliary histo‐
genesis or biliary differentiation. Epidemiologically, CC is a rare tumour with male predilec‐
tion. It composes 15% of primary liver cancer [100] but the relative incidence range of
cholangiocarcinoma is wide, from 5% in males and 12% in females in Osaka, Japan, to 90%
in males and 94% of primary liver cancer cases in females in Thailand. The age-standardized
incidence per 100 000 males ranges from 84.6 in Thailand to 2.8 in Osaka, Japan; 1.0 in
France or 0.9 in Italy. The known risk factors include association with ulcerative colitis and
primary sclerosing cholangitis [27]. The rate of cholangiocarcinoma in primary sclerosing
cholangitis patients is estimated as 10-20%. The presence of parasites, especially Clonorchis
sinensis and Opisthorchis viverrini, also increases the risk of cholangiocarcinoma. The high-in‐
cidence area in Laos and North and Northeast Thailand corresponds to the endemic area of
Opisthorchis viverrini. Korea has high rate of cholangiocellular cancer due to endemic spread
of Clonorchis sinensis. Clinically, the patients can present with painless jaundice [31], general
malaise, mild abdominal pain and weight loss [100]. Grossly, several types exist. Peripheral
tumours arise from portal bile ducts. Hilar lesions arise in large ducts. The diffuse intraduc‐
tal papillomatosis involves ducts as widespread carcinoma in situ lacking dominant mass
but leading to severe obstruction of bile flow. Histologically, cholangiocarcinoma has adeno‐
carcinomatous structure characterised by tubular complexes and moderate amount of des‐
moplastic stroma. The architectural variants include high-grade tumour lacking the
characteristic architecture, signet-ring cell tumour with presence of signet-ring cells, muci‐
nous type with extensive secretion of extracellular mucin, adenosquamous type with focal
squamous differentiation and spindle cell type with pseudosarcomatoid structure, presence
of malignant spindle cells and signs of epithelial differentiation. The tumour has no func‐
tional connection with bile excretory system although morphological connection in the form
of invasion or cancer in situ can exist. CC arises from ductal epithelium and not from hepa‐
tocytes. Due to these two reasons, presence of bile in the lumina of malignant glands is not
characteristic but eosinophilic or mucinous secretion can be present. Mucin stains as PAS or
mucicarmine can be positive [44]. The immunophenotype is derived from the immunophe‐
notype of bile duct epithelium, with expression of following cytokeratins: CK19 (100%), CK7
(80-100%), CK20 (20%). Diffuse cytoplasmic expression of CEA is found by polyclonal anti‐
body in almost all cases and is frequent by monoclonal antibody as well [27]. However, it is
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suggested that morphology cannot reliably distinguish cholangiocarcinoma from metastatic
pancreatic or colorectal cancer [31]. In case of pancreatic adenocarcinoma, the marked cellu‐
lar atypia disproportionally to better preserved architecture can be a clue. Colorectal adeno‐
carcinoma in typical cases is characterised by columnar morphology and diffuse intense
expression of CK20, CDX2 and CEA and lack of CK7. Other authors have drawn attention to
the impossibility to distinguish cholangiocarcinoma from metastatic gastric cancer and can‐
cer of gall bladder; metastatic pancreatic cancer also remains a problem [6]. The morphologi‐
cal differential diagnosis includes benign proliferation of bile ducts, hepatocellular
carcinoma and metastatic adenocarcinoma [27]. In order to discriminate between biliary ad‐
enoma and cholangiocarcinoma, invasion (including single invasive cells and perineural in‐
vasion) and cellular atypia should be sought for. Radiologic findings are helpful as bile duct
adenoma usually is smaller than 1 cm, but cholangiocarcinomas are large. The differential
diagnosis with hepatocellular carcinoma can rely both on morphology and immunopheno‐
type. Immunohistochemically, markers of biliary differentiation CK7 and CK19 are positive
in cholangiocellular carcinoma. Hep Par 1 can be used to exclude hepatocellular differentia‐
tion [6,29]. Proteomic analysis of differentially expressed proteins in peripheral cholangio‐
carcinoma is under research [101].
 
4. Vascular tumours
Cavernous haemangioma, epithelioid haemangiendothelioma and angiosarcoma are endo‐
thelial tumours representing the whole spectrum of biological potential. Haemangioma is
entirely benign although can cause complications due to large size; epithelioid haeman‐
gioendothelioma is notable for the peculiar structure leading to marked difficulties in the bi‐
opsy diagnostics, and angiosarcoma is a frank malignancy with grave prognosis. In
addition, angiomyolipoma will be discussed as well although it should be noted that this tu‐
mour has complex structure including rich vascularity as one component.
4.1. Cavernous haemangioma
Haemangioma is defined as benign endothelial tumour [102]. Due to bleeding risk, it is only
rarely seen in liver biopsy; in addition, the possibilities of radiological diagnostics are good
and the prognosis only rarely necessitates active treatment. However, epidemiologically the
lesion is the most common benign tumour of the liver with incidence 0.4% [27]. Clinically,
haemangioma usually are asymptomatic due to small size and slow expansive growth. Oc‐
casionally, a giant haemangioma (10-30 cm) can cause pain due to mass effect. Thrombosis
and bleeding can be dangerous complications. In neonates, blood shunting can lead to heart
failure. Grossly, haemangiomas are mostly solitary (90%), of small or moderate size (less
than 5 cm) and subcapsular. Microscopic structure is similar to cavernous haemangioma
elsewhere in the body. Cavernous, lake-like blood spaces can be seen, separated by hypocel‐
lular fibrous septa (Figure 4). Thrombosis can be present. The immunophenotype reflects
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the endothelial origin. In the rare situation, when biopsy is obtained from cavernous hae‐
mangioma, the differential diagnosis can include hepatic tumours with rich vascularity as
adenoma and cholangiocellular carcinoma. These are diagnosed by the presence and cyto‐
logical properties of liver cells. Other vascular tumours could be considered, including in‐
fantile haemangioendothelioma, angiomyolipoma, epithelioid haemangioendothelioma and
angiosarcoma. The infantile haemangioendothelioma can be recognized by capillary struc‐
ture and occurrence in infants [27]. Angiomyolipoma shows combination of fat, smooth
muscle and blood vessels with radiating immature smooth muscle cells. The higher cellular‐
ity and presence of fat are features incompatible with cavernous haemangioma. Epithelioid
haemangioendothelioma is discussed separately; the occurrence of vascular lakes usually is
not observed. Angiosarcoma can have cavernous architecture but the hallmark of it is the
cellular atypia.




Angiomyolipoma is defined as benign mesenchymal tumour with complex structure includ‐
ing immature smooth muscle, blood vessels and fat. Epithelioid cells and perivascular
HMB-45-positive cells can be present. Research of the tumour histogenesis has resulted in
the concept of PEComa, a tumour of perivascular epithelioid cells, showing myomatous, lip‐
omatous and melaninogenic differentiation. Epidemiologically, liver angiomyolipoma is
rare. It has been diagnosed in wide age range (10-86 years). In tuberous sclerosis, the inci‐
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dence of angiomyolipoma is increased. These patients may develop multiple angiomyolipo‐
mas in liver as well as kidney angiomyolipoma. Awareness of this condition is necessary to
escape over-diagnosis of metastatic malignant tumour. Clinically, the tumour can be asymp‐
tomatic. However, large tumours can cause pain; rupture and bleeding is also possible. By
radiologic studies, the tumour is hypervascular again. Grossly, angiomyolipoma usually is
solitary (except in tuberous sclerosis), measuring 0.8-36 cm. The microscopic picture (Figure
5) is straightforward if all three components are present in liver biopsy and have typical
structure. The smooth muscle cells can have epithelioid appearance leading to morphologi‐
cal similarity to liver parenchymal cells; the rich vascularity could lead to diagnostic confu‐
sion with hepatocellular tumour already earlier. The epithelioid cells sometimes can cause
suspicion for malignancy due to large nuclei and nucleoli. However, the nucleo: cytoplasmic
ratio remains low due to increased cell size.
Figure 5. The microscopic structure of angiomyolipoma. Note the peculiar, thick-walled blood vessels, immature
smooth muscle proliferation with high cellularity as well as the presence of fat. HE, OM 100x.
In difficult cases, IHC is helpful. The smooth muscle cells express actin (Figure 6) and fat
cells – S-100 protein. HMB-45 expression can be observed in perivascular epithelioid cells
(Figure 7). The differential diagnosis can include hepatocellular neoplasms or spindle cell
sarcomas. Actin expression and complex histological structure helps to exclude hepatocellu‐
lar origin of the tumour. Complex structure, combined immunophenotype and low prolifer‐
ation help to exclude sarcoma [27].
 
Primary and Metastatic Tumours of the Liver: Expanding Scope of Morphological and Immunohistochemical Details...
http://dx.doi.org/10.5772/52838
131
Figure 6. Actin-positive smooth muscle component in angiomyolipoma. IP, anti-actin, OM 100x.
Figure 7. Expression of melanosome protein HMB-45 in angiomyolipoma. IP, anti-HMB-45, OM 400x.
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4.3. Epithelioid haemangioendothelioma
Epithelioid haemangioendothelioma (EHE) is defined as intermediate-grade malignancy de‐
rived from endothelial cells. The mean age of patients is 47 years, ranging 12-86 years. The
clinical picture can include symptoms related to enlarging mass in liver (abdominal pain,
hepatomegaly) and tumour-related intoxication (fatigue, malaise, anorexia). Radiologically,
the tumour can be found by computed tomography. EHE can be radiologically avascular
[10,27,103]. This finding is probably related to fibrosis and scarcity of functioning blood ves‐
sels despite the endothelial origin of the tumour. Grossly, multiple tumours can involve liv‐
er or liver and lungs. In the lungs, epithelioid haemangioendothelioma is known also as
intravascular bronchioloalveolar tumour. Despite the multifocality (Figure 8), slow progress
is possible in our experience.
Biopsy material is usually sufficient to diagnose the tumour. However, in our experience,
immunohistochemical investigation is crucial in order to find out the presence of tumour
cells on the background of stromal fibrosis and reactive inflammation, to detect the endothe‐
lial origin and to evaluate the low biological potential as reflected by low to moderate prolif‐
eration activity by Ki-67 (Figures 9-11).
                                                                                                                                                                   
                  
Figure 8. Multiple foci of epithelioid haemangioendothelioma in liver biopsy. The tumour is highlighted by immuno‐
histochemical visualisation of vimentin regarding its mesenchymal nature. IP, anti-vimentin, OM 50x.
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Figure 9. Epithelioid haemangioendothelioma presenting as a fibrotic focus in liver biopsy. HE, OM 100x.
Figure 10. Loss of liver parenchyma due to infiltration of epithelioid haemangioendothelioma. IP, anti-cytokeratins
AE1/AE3, OM 200x.
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Figure 11. Expression of CD34 in epithelioid haemangioendothelioma. Note also the positive reaction in the lining of
a venule. IP,anti-CD34, OM 400x.
The tumour is growing within sinusoids and venules compressing the adjacent parenchyma.
As was mentioned, the expression of endothelial markers is typical. Focal expression of cy‐
tokeratin and/or actin is possible [103] and should not cause confusion if panel of immunos‐
tains is performed. Stromal fibrosis follows than and can become marked so that neoplastic
cells are obscured (Figure 9). Two cell types are described: epithelioid and dendritic. The
morphological differential diagnosis includes non-neoplastic fibrosis and/or inflammation
and granulation tissue, angiosarcoma and metastatic cancers with marked stromal fibrosis.
The non-neoplastic conditions can be ruled out by tumour architecture as revealed by im‐
munohistochemistry. Epithelial tumours can be excluded by the predominance of endothe‐
lial markers by IHC. Among the vascular malignancies, the diagnosis of epithelioid
haemangioendothelioma is preferred for lesions with low grade atypia, absence of frankly
malignant spindle cells, low proliferation, limited destruction of surrounding liver tissue
and absence of necrosis.
4.4. Angiosarcoma
Angiosarcoma is defined as malignant tumour of endothelial cells. Epidemiologically, it is
characterised by rare occurrence in the liver constituting 2% of primary hepatic malignan‐
cies [11]. Elderly (50-60-year-old) males represent the largest group of affected patients [27].
The described risk factors include history of thorotrast use for arteriography, exposure to vi‐
nyl chloride in the plastics industry where it has been used for polymerisation, arsenic com‐
pounds (used as insecticides, possibly present in wine and used in the treatment of
psoriasis), copper compounds, pesticides and other chemical carcinogens. In all cases, long
Primary and Metastatic Tumours of the Liver: Expanding Scope of Morphological and Immunohistochemical Details...
http://dx.doi.org/10.5772/52838
135
latent period (6-35 years) embarrass the data collection. The clinical picture can show signs
and symptoms of liver damage (hepatomegaly, local pain, jaundice), disorders of blood cell
function (anaemia, thrombocytopenia, disseminated intravascular coagulation), and tu‐
mour-related intoxication manifesting as weight loss. Ascites, bleeding into abdominal cavi‐
ty and liver failure is possible [27]. Grossly, multiple masses with signs of haemorrhage are
present. Morphologically, the cellular atypia as well as vascular differentiation can be ob‐
served in variable extent. High-grade tumours exhibit solid growth with few vascular
spaces. Immunohistochemically, endothelial markers CD31 and CD34 are expressed. How‐
ever, the immunophenotype can be not straightforward. In our experience, it is important to
use several endothelial markers. At first, the reactivity can be uneven [27]. Even more, CD34
is technologically beneficial antibody characterised with high affinity. However, during the
evaluation it is necessary to consider CD34 expression in non-endothelial tumours including
gastrointestinal stromal tumour and solitary fibrous tumour, among others.
 
5. Metastatic liver tumours
In Western countries, metastatic tumours represent the most common malignant liver le‐
sion with the rate 94-98% among all  malignant liver tumours [27].  Almost all  malignant
tumours, including carcinomas, sarcomas, melanomas and haematological malignancies, can
secondary involve the liver by haematogenous, lymphogeneous or transperitoneal spread.
Theoretically,  metastatic  tumour retains the morphological  characteristics  of  the primary
site. However, the balance between anaplasia and differentiation can shift towards anapla‐
sia in such degree that signs of differentiation towards specific tissue or cell type are hard‐
ly  recognisable.  Some  tumours  like  squamous  cell  cancer  and  melanoma  lack  specifity
regarding the organ of origin. Even adenocarcinomas retain few specific features. There‐
fore the differential diagnostics between primary and secondary liver tumours represents a
complicated practical task. Clinical data can be absent if metastatic liver lesion presents as
cancer of unknown origin. The diagnosis can be reached by logical analysis of morpholo‐
gy, IHC and molecular data. If the establishment of exact histogenesis is unsuccessful, the
biopsy investigation should be directed towards the analysis of treatment possibilities. Path‐
ologist  should comment in detail  morphological  and immunophenotype data that  could
either prove or disregard any particular type of treatment.
In case of liver metastasis, the primary tumour most frequently is located in colon, pancreas,
stomach, breast, oesophagus, genitourinary organs [100, 103]. Lung cancer can metastasize
to liver as well [6]. Neuroendocrine tumours, even small, can give rise to hepatic metastases.
The clinical course in this case can be prolonged and occasionally characterised by carcinoid
syndrome including flushing, diarrhoea and palpitations.
The spectrum of metastatic tumours in liver biopsies depend on the frequency of differ‐
ent tumours, the biological properties of different neoplasms predicting the possibility of
metastatic spread to liver as well as by the medical paradigm considering the indications
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for liver biopsies. In the files of single university hospital, metastatic tumours constituted
45% of tumours or tumour-like liver lesions. Adenocarcinoma was the most frequent histo‐
logical type of metastases (65.5%) comprising metastases of colorectal (48.2%), pancreatic
(13.5%), breast (13%), gastric (6.2%), lung (4.5%) and oesophageal cancer (3.7%). Neuroen‐
docrine  carcinomas  were  seen  frequently  (16%).  Lymphoma  constituted  0.4%  of  all  tu‐
mours [2]. Metastases in cirrhotic liver were rare [2]. In another study, including 130 cases
of  metastatic  liver disease,  gastrointestinal  tract  was found to be the most  common pri‐
mary  location  (45.3%)  of  cancer  metastasizing  to  liver  followed  by  neuroendocrine  tu‐
mours (10.7%) [104]. In children, neuroblastoma, nephroblastoma and rhabdomyosarcoma
are the most frequent source of metastases [103].
The spread to liver occurs in 5-10% of patients with Hodgkin’s lymphoma and 15-40% of
non-Hodgkin’s lymphoma cases at the time of diagnosis. Leukemias can involve the liver as
well. Grossly, large cell lymphoma can form masses similarly to carcinoma. In case of Hodg‐
kin’s disease, the size of nodules is variable. Leukemic infiltrate can be present without visi‐
ble mass lesion. Myeloid leukemias preferentially infiltrate sinusoids, lymphoid – portal
tracts, but hairy cell leukemia can involve both portal tracts and sinusoids forming small
blood containing cavities, surrounded by neoplastic cells [103].
Malignant melanoma (Figures 12-14) is one of the greatest challenges in diagnostic surgical
pathology [105] due to amelanotic, clear cell, sarcomatoid, small cell, haemangiopericytoid,
signet-ring cell, myxoid, metaplastic and rhabdoid forms. The diagnosis largely depends on
IHC. Evaluating the intermediate filaments, melanoma expresses vimentin. Despite the re‐
ported concerns of cytokeratin expression in melanoma, this is rare event (3%) in formalin-
fixed tissues. Similarly, the expression of glial fibrillar acidic protein and actin is observed in
1% of melanomas [105]. Interspersed normal cells should be excluded from evaluation of cy‐
tokeratin and actin reactivity. Melanoma is characterised by nuclear and cytoplasmic expres‐
sion of S-100 protein in 97.4-98%. S-100 protein can be observed in carcinomas, histiocytic
neoplasms and malignant peripheral nerve sheath tumour, therefore melanoma-specific an‐
tibodies, e.g., HMB-45 and MART-1/Melan-A must be included in the panel. Melanoma can
express bcl-2, CD10, CD68, CD56, CD57, CD99, CD117 antigens leading to diagnostic confu‐
sion with lymphoma, renal cell cancer, hepatocellular cancer, GIST, seminoma and other ne‐
oplasms. Expression of Melan-A is found also in metastatic adrenocortical carcinoma
(50-60%) that can be recognised by inhibin expression in around 70% of cases [6]. S-100,
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Figure 12. Diffuse sinusoidal spread of undifferentiated malignant tumour. By immunohistochemistry, metastatic
melanoma was revealed (see also Figure 13). HE, OM 400 x.
Figure 13. Intense perinuclear expression of melanosome protein HMB-45 in metastatic melanoma. IP, anti-HMB-45,
OM 400x.
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Figure 14. Lack of cytokeratins AE1/AE3 in metastatic melanoma. Note the unusual sinusoidal spread. IP, anti-AE1/
AE3, OM 400x.
Metastatic breast cancer expresses CK7 but not CK20. However, this immunophenotype is
shared by many adenocarcinomas. To identify the tumour as metastasis from breast primary
tumour, gross cystic disease fluid protein fraction-15 (GCDFP-15) and/or mammaglobin can
be detected. The specifity of GCDFP-15 is estimated as 99%, and the sensitivity ranges from
50 to 74%. Breast cancers of luminal molecular type express oestrogen (ER) and progester‐
one receptors (PR). Naturally, the expression of female steroid hormone receptors is shared
by ovarian and endometrial cancer. Nowadays the detection of ER and PR is routine in
breast cancer diagnostics but less experience is obtained with expression of hormone recep‐
tors in extra-genital carcinomas. The scientific studies report expression of ER in carcinoma
of lung, stomach and thyroid [105]. The cross-reactivity can be associated by certain anti‐
body clones. Also, HER-2 positive and triple negative molecular types of breast cancer are
more prone to develop visceral metastases. Thus, negative ER/PR expression cannot exclude
metastatic breast cancer, and positive findings should be interpreted with caution recognis‐
ing the possibility of metastatic ovarian or endometrial cancer and cross-reactivity or true
expression of hormone receptors in extra-genital tumour. ER/PR expression in lung or thy‐
roid tumour can be controlled by TTF-1 protein expression and/or evaluation for neuroen‐
docrine markers and calcitonin.
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Figure 15. Surfactant A in pulmonary adenocarcinoma. IP, anti-surfactant apoprotein A, OM 400x.
Adenocarcinoma, squamous cell cancer, small cell cancer and carcinoid are the most fre‐
quent lung neoplasms. Lung adenocarcinoma is characterised by expression of CK7 (100%)
and TTF-1 (60-75%).  Expression of  CK20 is  rare.  Cytokeratins 5/6  and 34betaE12 can be
present  but  are  not  dominant  in comparison with CK7.  Vimentin can be found in lung
adenocarcinomas.  Nuclear  expression of  TTF-1  and/or  cytoplasmic  expression of  surfac‐
tant apoprotein A (Figure 15) is an evidence of pulmonary origin. Small cell cancer express‐
es neuroendocrine markers and pan-cytokeratin. The expression of chromogranin A and CK
AE1/AE3 can be limited to perinuclear dot reactivity. Simultaneous detection of leukocyte
common antigen can be suggested to perform differential  diagnosis with haematological
neoplasm. Nuclear expression of TTF-1 protein is frequently present (Figures 16-18). The
high proliferation fraction by Ki-67 is characteristic albeit unspecific. The immunopheno‐
type of squamous cell cancer is unspecific and characterised by cytoplasmic expression of
CK5/6 and CK 34betaE12 in association with strong nuclear reactivity with p63 protein. CK7
can be present but is not dominant. TTF-1 protein is absent. Carcinoid is characterised by
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Figure 16. Small cell cancer. Note the “salt-and-pepper” chromatin and high mitotic activity. HE, OM 400x.
Figure 17. Granular cytoplasmic and perinuclear expression of chromogranin A in small cell cancer. IP, anti-chromog‐
ranin A, OM 400x.
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Figure 18. Nuclear TTF-1 expression in small cell cancer. IP, anti-chromogranin A, OM 400x.
              
Mesothelioma is characterised by expression of CK7, CK5/6, vimentin and calretinin (Figure
19). HBME-1 can be expressed as well but lacks specifity.
                                                                                                                                                                   
                     
Figure 19. Nuclear and cytoplasmic expression of calretinin in epithelioid mesothelioma.IP, anti-calretinin, OM 400x.
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Metastatic colorectal carcinoma can be recognised by diffuse intensive cytoplasmic expres‐
sion of CK20 and nuclear expression of CDX2 [108]. Carcinoid of the midgut and hindgut
also are positive for CDX2 [109].
Neuroendocrine tumours are characterised by strong cytoplasmic expression of chromogra‐
nin A and synaptophysin and negativity for Hep Par 1 [6]. CD56 is considered to be the
most sensitive neuroendocrine marker. In our experience, it shows reliable performance in
small or compressed biopsies making it especially valuable tool for the evaluation of scant
tissue material. Occasional CD56 expression in HCC is described [6].
Renal cell carcinoma is characterised by negativity for Hep Par 1 and CEA expression (by
polyclonal anti-CEA antibody). Unfortunately, the rate of RCC expression decreases from
50-80% in primary clear cell renal carcinoma and 60-90% in papillary renal cell cancer to
20% in metastatic renal cell carcinoma. CD10 can be present both in HCC and renal cell
carcinoma. Although the pattern of expression is different this can be difficult to evaluate,
especially in core biopsy. PAX-2 is advised as marker of metastatic renal cell carcinoma with
the expression rate 70-80%. Expression of vimentin is more characteristic in clear cell re‐
nal carcinoma (60-70%) than in hepatocellular carcinoma; chromophobe renal cell carcino‐
ma also is negative [6].
As tumour heterogeneity remains a source of problems [69] and the immunophenotype can
be inherently complex and subjected to cross reactivity, we recommend wide IHC panels in‐
cluding several markers for HCC and cholangiocarcinoma as well as markers for metastatic
tumour, including the organospecific antigens (see Tables 1-2).
Tumour Immunophenotype
Malignant melanoma Vim + CK AE1 / AE3 – S-100 + HMB-45 + MART-1 / Melan A +
Lung adenocarcinoma CK7+ CK20- CK34betaE12-/+ TTF-1+ Surfactant apoprotein A +
Small cell cancer CK AE1/AE3 + ChrA+ CD56 +TTF-1 +
Squamous cancer CK34betaE12+ CK7-/+ CK20 – p63+
NET CK AE1/AE3 + ChrA+ TTF-1 +/ - (lung) or CDX2 + (midgut, hindgut)
Breast cancer CK 7 + CK20 – MG +/– ER +/– PR +/–
Colorectal cancer CK20+ CK7- CDX2+ TTF-1-
Table 1. The immunophenotype of selected malignant tumours. Abbreviations in the Table: Vim, vimentin; CK,
cytokeratin; TTF-1, thyroid transcription factor 1; ChrA, chromogranin A; NET, neuroendocrine tumour; MG,
mammaglobin; ER, oestrogen receptor; PR, progesterone receptor
Antigen Valuable positive expression Notes
Glypican-3 Hepatocellular carcinoma Occasional positivity in non-hepatocellular tumour
Arginase-1 Hepatocellular carcinoma Sensitivity for hepatocellular carcinoma 96%
Normal liver tissue positive
Metastatic tumours rarely positive [69]
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Hep Par 1 Hepatocellular carcinoma Sensitivity for hepatocellular carcinoma around 50% [69]
Gastric carcinoma can be positive
AFP Hepatocellular carcinoma Sensitivity for hepatocellular carcinoma around 15% [69]
CD10 Renal cell carcinoma
Hepatocellular carcinoma
Negative in adrenal carcinoma
CK7 Cholangiocellular carcinoma
Metastatic cancers
Positivity does not exclude hepatocellular carcinoma




Positive tumours as pancreatic cancer (58%), squamous
carcinoma (75%), urothelial carcinoma (75%) and
cholangiocellular carcinoma (35%) can be distinguished




Positivity does not exclude hepatocellular carcinoma
CK20 Metastatic colorectal cancer Useful in conjuction with CK7 for initial grouping of cancers
showing adenocarcinomatous structure
CDX2 Metastatic colorectal cancer and NETs Heterogeneous focal expression in gastric and pancreatic
carcinomas
Mucinous ovarian cancers can be positive
Morules in endometrioid carcinoma are positive
Calretinin Mesothelioma
Adrenal cortical carcinoma
Sex cord-stromal tumours of the
genital tract
Squamous carcinoma frequently positive
Surfactant
apoprotein A
Lung adenocarcinoma. In our
experience possess high affinity and is
 useful, if positive
  Reactivity in thyroid cancer (43% in small group) has been
       reported




adenocarcinoma (75% of non-
mucinous type and 10% of mucinous
type), small cell cancer (pulmonary,
50-90%; non-pulmonary, 44-80%) or
thyroid cancer including papillary,
follicular and medullary but not
anaplastic carcinoma [69]
    Regarding pulmonary adenocarcinoma, less subjected to
   heterogeneity-related evaluation problems than surfactant
    apoprotein A
  Endometrial (17%) or breast (2.4%) cancer occasionally
    positive [69]
TTF-1, cytoplasmic
expression:
 Hepatocellular carcinoma Expression in benign liver parenchyma is present
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  Breast, ovarian or endometrial cancer,
 endometrial stromal sarcoma
 Non-gynaecologic cancers can be occasionally positive,
including lung cancer (4-15-67%)
CD117 GIST
Seminoma
CD34 is co-expressed in GISTs
PLAP is co-expressed in germ cell tumours
Mammaglobin Breast cancer High heterogeneity
Sensitivity for breast cancer 40-85%
Ovarian (17%), endometrial (40-70%) and endocervical
(30%) carcinoma can also be positive [69]
GCDFP-15 Breast cancer Sensitivity for breast cancer 50-60%
High heterogeneity
Not associated with mammaglobin thus simultaneous
evaluation can be recommended [69]
PSA Prostatic cancer Negative in 5% high-grade prostate cancers. Reactivity in
few breast carcinomas and rectal NETs have been observed
[69]
Pax8 Thyroid cancer
Female genital tract carcinomas
Renal cell cancer
Sensitivity for thyroid cancer 79-100% and for renal cancer
71-98%
Breast cancer is negative. Positivity is useful to discriminate
breast cancer from ovarian or endometrial cancer
NETs can be positive
P63 Squamous cell cancer
Urothelial carcinoma
Table 2. Panel of antibodies for liver biopsy evaluation. Abbreviations in the Table: AFP, alpha-fetoprotein; CK,
cytokeratin; NET, neuroendocrine tumour; TTF-1, thyroid transcription factor 1; GIST, gastrointestinal stromal tumour;
PLAP, placental alkaline phosphatase; GCDFP-15, gross cystic disease fluid protein-15; PSA, prostate specific antigen
6. Cystic biliary tumours
The cystic biliary tumours are defined by cystic structure and development of / differentia‐
tion towards intrahepatic bile duct epithelium. The group includes malignant biliary cysta‐
denocarcinoma and benign biliary cystadenoma. Epidemiologically, cystic biliary tumours
represent rare entities, with incidence of biliary cystadenocarcinoma approximately 1/10
million (corresponding to 0.01/100 000) and of biliary cystadenoma 1/100 000 - 5/100 000
[110]. Biliary cystadenocarcinoma is diagnosed mostly at the age 50-60 years [100]. Biliary
cystadenoma is diagnosed in younger patients: mean age 40.6 (range 30-51) vs. 51.3 (range
41-63) years in biliary cystadenocarcinoma group [14]. In other studies even larger age dif‐
ference (17 years) is found between patients affected by benign and malignant cystic biliary
tumours, respectively [111-112]. Cystic biliary tumours are more common in women:
80-100% of biliary adenoma and 63-71.4% of biliary cystadenocarcinoma are described in fe‐
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male [14]. The clinical picture reflects the presence of mass lesion and is dominated by ab‐
dominal pain [113]. The other manifestations and complications include jaundice,
cholangitis, tumour rupture [114], haemorrhage [115], compression of the portal or caval
veins with possible subsequent ascites [113], hemobilia [12] and mucobilia [116]. Notably,
the tumour can progress slowly [117] with the clinical history of biliary cystadenocarcinoma
as long as 10-15 years [112,118]. The long course is is in accordance with the low grade of
malignancy and gradual development of tumour through stages of increased epithelial pro‐
liferation, dysplasia, in situ cancer and, finally, invasive cancer. Thus, long anamnesis of
cystic hepatic mass does not exclude the possibility of malignant tumour and the need for
careful follow-up if the cyst is not removed by operation. Although biopsy can be consid‐
ered in cases with unclear differential diagnosis, it is not the first choice because of the fol‐
lowing considerations. First, simple liver cyst is the main differential diagnosis of cystic
biliary tumours. Although biliary cystadenocarcinoma is rare, liver cysts have high preva‐
lence being present in 2.5% of the population [119] and cannot be distinguished from cystic
biliary tumours on the basis of CA19-9 and CEA levels [14,114]. However, core biopsy is un‐
likely to yield sufficient tissue in case of simple cyst or cystadenoma; it also is not suitable
for the diagnostics of focal malignancy and rarely can lead to peritoneal carcinomatosis [13].
Therefore radiological diagnostics, especially computed tomography, is essential [117].
Grossly, biliary cystadenocarcinoma is multicystic. Internal mural nodules are irregularly
distributed in the walls. The tumour most frequently is located within the liver (83%). Extra-
hepatic bile ducts (13%) or the gall bladder (0.02%) has been affected by this tumour as well
[14]. The size of cystic biliary tumours (1.5-30 cm) is not helpful in the differential diagnos‐
tics between simple hepatic cyst and cystic biliary tumours; it also has no correlation with
malignant biological potential [120]. The metastatic spread of biliary cystadenocarcinoma
can affect the liver, regional lymph nodes in the hepatoduodenal ligament, lungs, pleura or
peritoneum [100]. Histologically, biliary cystadenocarcinoma is characterised by clear-cut
signs of malignancy: cellular atypia, particularly nuclear polymorphism, mitotic activity and
invasion into surrounding stroma. The tumour architecture is cystic and papillary. The be‐
nign counterpart of biliary cystadenocarcinoma, the biliary cystadenoma lacks the malig‐
nant features [100] and is composed by either mucinous or serous benign epithelium. Most
of cystic biliary tumours possess characteristic mesenchymal, ovarian–type stroma. Hypo‐
thetically, these tumours arise from bile ducts proximal to the hilum of the liver and share
the cystic structure and presence of peculiar ovarian-type mesenchymal stroma with muci‐
nous cystic tumours of the pancreas and retroperitoneum, leading to the hypothesis that ec‐
topic ovarian stroma during embryogenesis can become incorporated along the biliary tree,
in the pancreas and retroperitoneal space and cause the proliferation of the adjacent epitheli‐
um by production of the hormones and growth factors [121]. Origin from intrahepatic peri‐
biliary glands [122] or from ectopic rests of primitive foregut sequestered in the liver [114]
has been hypothesised. Development from pluripotential stem cells is suggested on the ba‐
sis of the presence of albumin messenger RNA and biliary type cytokeratins in the tumour
cells [123]. Biliary cystadenocarcinoma without mesenchymal stroma more frequently arises
in males and carries poorer prognosis in comparison with the tumour possessing mesenchy‐
mal stroma [122]. By immunohistochemistry, increasing proliferative activity by Ki-67 ex‐
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pression as well as increasing p53 protein expression from adenoma to carcinoma was
shown in biliary cystadenocarcinoma without ovarian-type stroma [124]. Expression of cyto‐
keratin (CK) 7 and absence of CK20, CEA, alpha-fetoprotein, calretinin, CD31 and chromog‐
ranin is described [125]. However, presence of CK20, although typical for colorectal cancer,
is described in cholangiocarcinoma, especially non-peripheral [126]. It might be expected in
biliary cystadenocarcinoma with growing awareness about this entity.
There is evidence showing that at least some cases of biliary cystadenocarcinoma originate
from pre-existing biliary cystadenoma. These data include the age difference between biliary
cystadenocarcinoma and biliary adenoma patients [14] as well as morphologic findings of
malignant transformation in a lesion with focally innocuous structure [127].
Radiologically, presence of internal septations allows excluding a simple cyst. Vascularity of
septa is characteristic for cystic biliary tumours [14] and is considered by some specialists to
be more reliable in distinguishing biliary cystadenoma from cyst than the simple presence of
septations [117]. Biliary cystadenoma is characterised by smooth and thin internal septa, but
presence of enhanced mural nodules in the outer wall or septa is the most important sign of
malignancy. Calcification is not frequent but has been found specific for malignancy by
some [14] but not all [119] authors as far as cystic biliary tumours are concerned. Size, num‐
ber of septations or location of the neoplasm does not help to differentiate between benign
or malignant cystic biliary tumours [14]. Some authors have postulated that preoperative
differentiation between biliary adenoma and cystadenocarcinoma by radiologic imaging is
not possible therefore liver resection should be performed for all cystic biliary tumours
[120]. This assumption is based on the experience that internal papillae with arterial en‐
hancement may be present in both tumours so that computed tomography and magnetic
resonance imaging yield overlapping data.
The clinical differential diagnosis of cystic liver lesions, entering the differential diagnosis of
biliary cystadenocarcinoma, include developmental, neoplastic, inflammatory and traumatic
lesions as simple bile duct cyst, polycystic liver disease, biliary hamartoma, cystically degen‐
erated cases of other primary or metastatic liver tumours, abscesses, hydatid cyst, extrap‐
ancreatic pseudocyst, hematoma and biloma [119,128].
7. Conclusions
In conclusion, wide variety of neoplastic processes can affect the liver. Most of non-cystic
tumours can be reliably diagnosed in liver biopsy. Several demographic and clinical data
should be submitted along with the liver biopsy. Patient’s age and presence or absence of
clinical symptoms must be known. If there is history of contraceptive use it should be report‐
ed. Radiological data have high relevance: the size, localisation in respect to liver capsule and
number of focal liver lesions should be known to the pathologist. The vascularity should be
described. Knowing these data, pathologist should evaluate the haematoxylin-eosin stained
specimen. Wide panel of immunohistochemical stains can be recommended than.
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